



Implanet presents independent radiological results of the JAZZ Band at the SRS 52nd Annual Meeting & Course

- **Significant axial derotation of the spine***
- **Optimal sagittal alignment***

**compared with the traditional 'All-Screw' technique*

Bordeaux, Boston, September 5, 2017 – 8:00 AM CEST – IMPLANET (Euronext Growth: ALIMP, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces the publication of a White Paper entitled “*How to optimize axial correction without altering thoracic sagittal alignment in hybrid constructs with sublaminar bands: description of the ‘frame technique’*”, which presents the results of clinical analyses based on 3D radiological reconstructions with EOS 3D Service.

This independent study, conducted at Robert Debré Hospital (APHP, Paris Diderot) Orthopedic Pediatric Surgery department, represents another step in the JAZZ system’s clinical validation, highlighting its safety and efficacy in the treatment of idiopathic scoliosis.

The study analyzed 3D radiological reconstructions of 60 patients treated with the ‘frame’ technique, using JAZZ Band and JAZZ Frame implants. The rigid frame facilitates posteromedial translation, resulting in comparable axial rotational correction as compared to the traditional ‘All-Screw’ technique, while preserving the unique advantage of sublaminar implants for restoration of sagittal balance.

“Although, for many surgeons, pedicle screws represent the Gold Standard in treating idiopathic scoliosis, sublaminar bands should be considered as part of the therapeutic arsenal, as their beneficial action on the sagittal balance has been proven. Their excellent biomechanical properties enable considerable correction forces to be applied without running the risk of pulling out the concave screws”, says Professor Brice Ilharreborde, M.D., Ph.D., continuing: *“The frame technique combined with the use of JAZZ implants makes it possible to optimize axial correction while respecting the patient’s sagittal alignment”*.

Ludovic Lastennet, CEO of Implanet, adds: *“This highly-anticipated study confirms that the use of JAZZ implants, combined with the frame technique, offers surgeons a safe and efficient alternative to traditional techniques. These results notably confirm the derotation capabilities of JAZZ implants associated with the JAZZ Frame. Henceforth, we have objective and irrefutable clinical evidence concerning the added value provided by JAZZ implants and the frame technique favoring their use. These results will be presented to surgeons and our commercial partners at the SRS Annual Meeting, which begins today in Philadelphia and will be attended by more than 1,300 global specialists in complex spine surgery.”*

The White Paper is available on the Company’s website at the following address: www.implanet.com

Implanet will participate in the following scientific conferences:

- Eurospine – Dublin (October 11 through 13, 2017)
- NASS – North American Spine Society – Orlando (October 25 through 28, 2017)
- SOFCOT – Paris (November 6 through 9, 2017)

About the Scoliosis Research Society

The Scoliosis Research Society Annual Meeting & Course with about 1,400 attendees is a forum for the realization of the Society's mission and goals, to foster the optimal care of all patients with spinal deformities. Presentations at the Annual Meeting & Course are given by leading experts in the field and have value for health care professionals who treat spinal deformities at all levels and in all ages. Over 125 papers will be presented on an array of topics, including adolescent idiopathic scoliosis, growing spine, kyphosis, adult deformity, trauma, neuromuscular scoliosis and tumors. The Annual Meeting & Course is open to anyone involved in the treatment of spinal deformities including spine surgeons, residents and fellows, physician assistants, nurses and other allied health professionals, and researchers. The presentations selected from over 1,600 submissions provide valuable information to all individuals caring for patients with spinal deformities. www.srs.org

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Euronext™ Growth market in Paris.

IMPLANET

Ludovic Lastennet

CEO

Tel. : +33 (0)5 57 99 55 55

investors@implanet.com

NewCap

Investor Relations

Florent Alba

Tel. : +33 (0)1 44 71 94 94

implanet@newcap.eu

NewCap

Media Relations

Nicolas Merigeau

Tel. : +33 (0)1 44 71 94 98

implanet@newcap.eu

AlphaBronze

US-Investor Relations

Pascal Nigen

Tel.: +1 917 385 21 60

implanet@alphabronze.net

Disclaimer

This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company's website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.